EU-CAYAS-NET consortium representatives discuss a new guideline to support the transition to long-term care for young cancer survivors.

The topical JAK inhibitor ruxolitinib has been recommended by the NICE for eligible patients with non-segmental vitiligo.

SABRE project leads discuss landmark changes in total hip BMD as a surrogate for fracture risk reduction in postmenopausal osteoporosis.

Clinical Excellence in Respiratory Care event returns in May to showcase the latest innovations for respiratory service delivery.

Persistent chemotherapy-induced alopecia markedly impacts self-esteem, treatment adherence and overall quality of life in cancer survivors. This expert commentary by Professor Azael Freites-Martinez, ...

Significant reductions in influenza- and pertussis-related hospitalisations and emergency department attendances have been observed among infants younger than six months born to mothers vaccinated ...

The latest National Early Inflammatory Autoimmune Diseases Audit reveals persistent delays in patient presentation, wide regional variation in remission rates and a high burden of mental health ...

Initiating treatment with a sodium–glucose cotransporter-2 (SGLT2) inhibitor rather than a glucagon-like peptide-1 receptor agonist (GLP-1RA) is associated with better renal outcomes in people with ...

The potential for everyday wireless signals to be used to spot common respiratory diseases without scans, needles or physical contact has been evaluated in a recent study, showing that changes in ...

Incidentally detecting splenomegaly during routine imaging is associated with a substantially increased risk of underlying haematological cancer and liver disease once specific spleen size thresholds ...

Survivors who report a poorer health-related quality of life (HRQOL) several months after cardiac arrest experience significantly reduced long-term survival, according to a large study, underscoring ...

Combining metastases-directed stereotactic radiotherapy (SRT) with modern biological cancer therapies is associated with a low risk of severe adverse events, even when systemic treatment is continued, ...